Session Title: Vascular Diseases II
Session Date/Time: Friday 27/09/2013 | 11:00-12:30
Paper Time: 11:24
Venue: Hall F (Level 2)
First Author: M.Nicolo ITALY
Co Author(s): C. Eandi C. Alovisi F. Cardillo Piccolino F. Grignolo
To compare the short-term and long-term efficacy, safety and costs of half-fluence and half-dose photodynamic therapy (PDT) in chronic central serous chorioretinopathy (CSC).
Multicenter retrospective comparison study
Retrospective review of 56 patients affected by chronic CSC, including 28 patients (31 eyes) who received half-fluence PDT and 28 patients (29 eyes) who received half-dose PDT. Best-corrected visual acuity (BCVA), central retinal thickness (CRT) and resolution of subretinal fluid on optical coherence tomography at 1 month and at the last-follow-up visit (LFU) were assessed. Cost analysis was also performed
BCVA improved significantly (p<0.001) both in the half-fluence group from 0.70 (±0.23) to 0.87 (±0.21) and in the half-dose group from 0.76 (±0.16) to 0.87 (±0.16) at the LFU. There was no difference in final BCVA between the 2 groups. At 1 month a complete resolution of subretinal fluid was observed in 19 (61.3%) half-fluence treated eyes and in 25 (86.2%) half-dose treated eyes (p =0.04). At the LFU, a complete resolution of sub-retinal fluid was achieved in 26 (83.9%) half-fluence treated eyes and 29 (100%) half-dose treated eyes (p = 0.0529; OR, 5.20; 95% CI, 1.75-15.42). Nine (25.8%) eyes in the half-fluence group and 5 (17.2%) eyes in the half-dose group had at least one recurrent episode of subretinal fluid (OR, 1.96; 95% CI, 0.57-6.76). Overall there were 15 and 5 recurrences in the half-fluence PDT and half-dose PDT respectively (p=0.06; OR, 4.5; 95% CI, 1.36-14.84). The overall cost of half-fluence PDT was twice the cost of half-dose PDT.
Half-dose PDT induced a more rapidly reabsorption of the fluid, a more lasting effect and a halving of the costs respect to half-fluence PDT